甲状旁腺素(Shire Plc)(Parathyroid Hormone(Shire Plc)) - 药物靶点：PTH1R_在研适应症：甲状旁腺功能减退症，低钙血症_专利_临床

概要

基本信息

药物类型

激素

别名

Parathormone、Parathormone (human recombinant)、Parathyrin

+ [25]

靶点

PTH1R

作用方式

激动剂

作用机制

PTH1R激动剂(甲状旁腺激素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

甲状旁腺功能减退症低钙血症

非在研适应症

骨折自发性骨折家族性高钙尿症性低钙血症+ [3]

原研机构

Shire Plc

在研机构

Takeda Pharmaceuticals U.S.A., Inc.Takeda Pharmaceuticals International AG

非在研机构

Shire Plc

NPS Pharma Holdings Ltd.

Entera Bio Ltd.

+ [1]

权益机构

NPS Pharmaceuticals, Inc.

GSK Plc

最高研发阶段批准上市

首次获批日期

欧盟 (2006-04-24),

绝经期后骨质疏松

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 61834

来源: *****

关联

31

项与甲状旁腺素(Shire Plc) 相关的临床试验

NCT03878953

/ Withdrawn临床3期

A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism

This clinical study aims to evaluate the safety and efficacy of repeated dosing of recombinant human parathyroid hormone (rhPTH[1-84]) in Japanese participants with chronic hypoparathyroidism for a 26-week period.

开始日期2022-08-31

申办/合作机构

Shire Plc

ChiCTR2300067899

/ Recruiting临床4期IIT

Clinical study of recombinant human parathyroid hormone in the treatment of osteoradionecrosis of the jaws

开始日期2022-06-30

申办/合作机构-

NCT05137730

/ Completed临床1期

A Randomized, Open-label, Single-center, Single-dose Study to Evaluate the Relative Bioavailability of a New Formulation Compared With the Approved Formulation of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) and to Assess Dose Linearity of the New Formulation in Healthy Subjects

The main aim of Part I of this study is to evaluate the relative bioavailability of a new formulation compared with the approved formulation when a single dose of rhPTH(1-84) is given to healthy volunteers. Bioavailability is the ability of a drug to be absorbed and used by the body. In Part II, the main aim is to assess the dose linearity of the new formulation.
Participants will receive 2 doses in Part I and 4 doses in Part II.
Participants need to visit their doctor approximately 14 days and 30 days after the last dose of study drug.

开始日期2021-11-29

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

[+1]

100 项与甲状旁腺素(Shire Plc) 相关的临床结果

登录后查看更多信息

100 项与甲状旁腺素(Shire Plc) 相关的转化医学

登录后查看更多信息

100 项与甲状旁腺素(Shire Plc) 相关的专利（医药）

登录后查看更多信息

4,280

项与甲状旁腺素(Shire Plc) 相关的文献（医药）

2025-12-31·CLINICAL AND EXPERIMENTAL HYPERTENSION

Parathyroid hormone and vitamin D modulate nocturnal blood pressure dipping: a retrospective cohort study in primary hypertension

Article

作者: Liang, Xiaohui ; Xu, Yixin ; Deng, Changjiang

BACKGROUND:

Non-dipper hypertension, defined by reduced nocturnal blood pressure (BP) decline, increases cardiovascular risk. Calcium-phosphate metabolism (parathyroid hormone [PTH], vitamin D [25(OH)D]) may influence circadian BP rhythms, but their independent roles remain unclear.

OBJECTIVE:

To investigate associations between PTH, 25(OH)D, and nocturnal BP dipping in primary hypertension, addressing prior inconsistencies.

METHODS:

This retrospective cohort included 585 hypertensive adults stratified by nocturnal systolic BP dipping (dippers [≥10% decline, n = 250]; non-dippers [<10%, n = 335]) using 24-hour ambulatory monitoring. Serum PTH, 25(OH)D, renal/metabolic parameters, and vascular indices were analyzed. Multivariate linear regression assessed associations with dipping, adjusted for age, sex, renal function, and arterial stiffness.

RESULTS:

Non-dippers showed elevated PTH (median: 5.23 vs. 4.70 pmol/L, p = .011) and lower 25(OH)D (30.89 vs. 36.79 nmol/L, p < .001). Adjusted models confirmed PTH (β=-0.21, 95% CI:-0.34--0.08; p = .002) and 25(OH)D (β = 0.03, 95% CI:0.01-0.04; p < .001) as associated factors of dipping. Although statistically significant, these correlations were modest and suggested possible trends rather than strong causal relationships. Age/sex effects on BP patterns became nonsignificant after adjusting for calcium-phosphate markers.

CONCLUSION:

Calcium-phosphate dysregulation (elevated PTH, low vitamin D) independently contributes to non-dipping, suggesting biomarker-guided approaches for circadian BP control. Demographic disparities in dipping may reflect underlying mineral metabolism disturbances. Prospective trials should explore calcium-modulating therapies (e.g. vitamin D supplementation) in non-dipper hypertension.

2025-12-01·Current Osteoporosis Reports

PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1–84 and Palopegteriparatide

Review

作者: Tabacco, Gaia ; Naciu, Anda Mihaela ; Palermo, Andrea ; Donovan, Yu Kwang Tay ; Zavatta, Guido

PURPOSE OF REVIEW:

to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1-84) and palopegteriparatide, for the management of hypoparathyroidism.

RECENT FINDINGS:

neither PTH (1-84) nor PTH(1-34) have been shown a clear and consistent favorable impact on the 24 h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food & Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1-34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT. Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.

2025-09-01·CLINICA CHIMICA ACTA

Parathyroid hormone reference intervals revisited: a data-driven approach for age-related reference intervals in adults

Article

作者: Hataysal, Esra Paydaş ; İşman, Ferruh Kemal

BACKGROUND:

Parathyroid hormone (PTH) plays a critical role in calcium-phosphate homeostasis. Accurate interpretation of PTH levels requires reliable reference intervals (RIs). Our aim was to establish RIs for PTH using real-world data from a high-volume tertiary care laboratory.

METHODS:

This retrospective study included 22,662 adults aged 18-79 years, selected from 47,311 individuals who presented to the Islab-2 central laboratory between January 2021 and April 2025. Patients were excluded if they were referred from nephrology, endocrinology, or general surgery clinics, or if they had an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2, vitamin D < 50 or > 250 nmol/L, albumin < 35 or > 55 g/L, alkaline phosphatase (ALP) > 150 U/L, alanine aminotransferase (ALT) > 50 U/L, phosphate < 0.8 or > 1.45 mmol/L, or calcium < 2.15 or > 2.6 mmol/L. All biochemical analyses were performed using the Roche Cobas® 8000 system (Roche Diagnostics, Mannheim, Germany). Outliers were excluded using Horn's method with Tukey's interquartile fences (k = 1.5), and the need for partitioning by age, sex, or season was evaluated with the Harris-Boyd z-tests. The RIs were calculated using a non-parametric method along with their 2.5th and 97.5th percentile values with 90 % confidence intervals (CIs).

RESULTS:

PTH RIs increased with age. Compared to the manufacturer's non-age-stratified RI (1.6-6.9 pmol/L), 61 % of patients aged > 50 previously classified as hyperparathyroid were reclassified as normal using age-adjusted RIs. Additionally, up to a 43 % difference in the upper reference limit (URL) was observed when comparing the URL of the youngest age group (18-29 years) with those of the oldest age group (60-79 years).

CONCLUSION:

Age-specific PTH RIs are essential for accurate diagnosis, particularly in older adults, where uniform thresholds may lead to misclassification of normocalcemic primary hyperparathyroidism. Implementing these RIs could optimize clinical decision-making and reduce unnecessary interventions. Further validation across diverse populations and assay platforms is warranted.

38

项与甲状旁腺素(Shire Plc) 相关的新闻（医药）

2025-06-05

·复星医药

2025 ERA大会抢先看 | CKD-MBD领域研究新进展

2025年第62届欧洲肾脏协会(ERA)大会-欧洲肾脏病年会将于2025年6月4-7日在奥地利维也纳举行，ERA肾脏病年会将为与会者提供肾脏领域相关主题的最新进展，重点介绍最新的基础和临床研究结果。本文重点关注高磷血症和继发性甲状旁腺功能亢进（SHPT）疾病领域的新进展，筛选了大会上发表的新型降磷药盐酸替那帕诺片和新一代拟钙剂盐酸依特卡肽注射液的6篇摘要，会议召开在即，本文整理了入选研究的核心信息，以飨读者。盐酸替那帕诺片3篇摘要信息01摘要编号：No.2340英文标题：Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect中文标题：替那帕诺联合磷酸盐结合剂给药可产生协同降磷效应研究描述：研究探讨替那帕诺单用或联合传统磷结合剂对血液透析患者高磷血症的疗效及协同机制。通过对20例患者（7例单用替那帕诺，13例联合磷结合剂）进行3个月干预治疗。结果显示：替那帕诺显著降低血清磷水平（从7.6±1.1降至5.9±1.2 mg/dl）和肠道磷吸收量（从550±102降至450±110 mg/day），且联合治疗组的降磷幅度（ΔPpre=1.7±0.9 vs. 单用组1.2±0.6，p=0.027）和磷吸收减少量（ΔPA=125±65 vs. 55±62，p=0.016）均显著优于单用组。研究证实替那帕诺通过抑制肠道磷吸收，与传统磷结合剂的直接结合作用形成互补，产生协同效应，为优化高磷血症治疗提供了新策略。作者及单位：Hiroshi Kikuchi1, Hisaki Shimada2, Ryo Karasawa102摘要编号：No.827英文标题：Effect of Tenapanor on Serum Phosphorus (Pi), Creatinine (Cre), and Body Weight (BW) Gain in Hemodialysis Patients中文标题：替那帕诺对血液透析患者血清磷（Pi）、肌酐（Cre）及体重增加（BW）的影响研究描述：研究针对44名维持性血液透析患者，评估了替那帕诺对血清磷（Pi）、肌酐（Cre）及透析间期体重增长（ΔBW）的长期影响。结果显示，用药3个月后，26例患者血清磷显著下降（部分患者减少磷酸盐结合剂用量），12例肌酐降低，13例体重增长减少；且血清磷下降与体重增长减少（R=0.35）及肌酐降低（R=0.38）呈正相关。研究表明，替那帕诺可能通过抑制肠道钠吸收稳定降低血磷水平，并减少液体潴留，但其对肌酐的影响机制仍需进一步探索。作者及单位：Shu Iwasawa1, Takeshi Nakanishi1 2, Takahiro Morino1, Shinichi Nariyama1, Tetsuya Noguchi1, Takahiro Kuragano2；1Gojinkai Sumiyoshigawa Hospital, Kobe, Japan; 2Hyogo Medical University, Nishinomiya, Japan03摘要编号：No.3639英文标题：Effect of Low-Dose Tenapanol on Inflammation in Hemodialysis Patients中文标题：低剂量替那帕诺对血液透析患者炎症的影响研究描述：一项针对25例血液透析患者的前瞻性临床研究显示，低剂量替那帕诺治疗12周后，血磷水平显著降低（6.4→5.2 mg/dL，P=0.0003），肠道功能改善（Bristol评分提升，P=0.003），但炎症标志物TNF-α异常升高（16.1→23.1 pg/mL，P=0.001），CRP仅轻度波动且保持正常范围。16%患者因腹泻中止治疗，无严重安全性事件。结果表明该药物短期降磷效果明确，但炎症反应需进一步验证，长期安全性仍需评估。作者及单位：Misaki Moriishi1, Takumi Matsumoto2, Mai Ogasawara1, Nanako Mashima1, Maya Oda1；1Nakajima Tsuchiya Clinic, HIroshima, Japan; 2Tsuchiya General Hospital, Hiroshima, Japan盐酸依特卡肽注射液3篇摘要信息04摘要编号：No.1337英文标题：The role of Intravenous Etelcalcitide in Haemodialysis Patients with mid-range serum Parathyroid Hormone levels.中文标题：静脉注射依特卡肽在中等血清甲状旁腺激素水平的血液透析患者中的作用研究描述：研究评估静脉注射拟钙剂依特卡肽对49例血清PTH中等水平（中位130.0 pmol/L）血液透析患者的疗效与安全性，结果显示：治疗中位PTH降幅达73.4%（降至38.3 pmol/L），89.7%长期用药患者实现PTH降低≥30%，骨代谢指标碱性磷酸酶（ALP）在治疗2年后下降47.2%；安全性方面，34.9%患者出现无症状低钙血症（血钙< 2 mmol/L），通过补钙、维生素D及剂量调整可有效控制风险，提示该药对PTH<300 pmol/L患者具有显著临床获益，但需更大规模研究验证长期预后。作者及单位：Shilpa Vijayasrinivasan 1 , Claire Edwards 2 , Anisha Tanna 2 , Megan Griffith 1 , Zohreh Nazari 1 , Oshini Shivakumar 3 , Neill Duncan 2； 1Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; 2Northwick Park Hospital Dialysis Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; 3 Imperial College London, London, United Kingdom05摘要编号：No.1340英文标题：Transfer of patients from cinacalcet to etelcalcetide: a retrospective cohort study in real world practice中文标题：患者从西那卡塞转换为依特卡肽的临床实践研究：一项真实世界回顾性队列分析研究描述：研究是一项针对302例血液透析患者的回顾性多中心队列研究，旨在评估从西那卡塞转为依特卡肽治疗SHPT的临床效果。结果显示：治疗6个月后49.7%患者达到甲状旁腺激素（PTH）目标范围（300-599 pg/mL），其中基线PTH 600-1000 pg/mL组达标率显著高于>1000 pg/mL组（79.3% vs 36.4%，p<0.001）。存在甲状旁腺腺瘤（体积>500mm³或最大径>10mm）的患者达标率显著降低（48% vs 85.6%无腺瘤组，p<0.001），尤其在基线PTH>1000 pg/mL时差异更显著（25% vs 57.9%，p=0.016）。研究证实依特卡肽可有效控制SHPT，但基线PTH过高及甲状旁腺腺瘤存在会显著降低疗效，且腺瘤比高PTH更能预测治疗反应不足，换药过程中未发现新的安全性问题。作者及单位：Ekaterina Parshina 1 , Roman Gerasimchuk 2 3 , Alexander Zemchenkov 3 , Aleksei Zulkarnaev 4；1Saint Petersburg State University Hospital, Saint Petersburg, Russia; 2Northwestern State Medical University n.a. I.I.Mechnikov, Saint Petersburg, Russia; 3City Mariinsky Hospital, Saint Petersburg, Russia; 4Moscow Regional Research and Clinical Institute, Moscow, Russia06摘要编号：No.3219英文标题：Comparative effectiveness of etelcalcetide versus cinacalcet for the treatment of secondary hyperparathyroidism in patients in haemodialysis: a population-based study in Lazio, Italy中文标题：依特卡肽与西那卡塞治疗血液透析患者SHPT的有效性：意大利拉齐奥地区的一项基于人群研究研究描述：研究在意大利拉齐奥地区纳入652名血液透析患者，比较了依特卡肽与西那卡塞治疗SHPT的疗效。结果显示：PTH控制：两种药物均显著降低血清PTH水平（依特卡肽从605.2降至372.9 pg/mL，西那卡塞从577.9降至285.1 pg/mL），目标达标率在24个月时分别提升至59.3%和63.3%。血磷改善：依特卡肽组达标率从23.0%升至36.0%，西那卡塞组从19.1%升至26.7%，但仅西那卡塞组平均血磷水平显著下降。血钙变化：依特卡肽组血钙达标率下降，而西那卡塞组无显著变化，两组平均血钙水平保持稳定。结论表明两种药物对SHPT控制效果相近，但既往研究提示依特卡肽可能具有更优的生存获益（死亡率降低趋势）。作者及单位：Micol Manzuoli 1 , Ursula Kirchmayer 2 , Nera Agabiti 2 , Laura Angelici 2 , Sandro Feriozzi 3 , Carlo Massimetti 1 , Antonio Addis 2 , Claudia Marino 2 ；1ASL Viterbo, UOC Nephrology and Dialysis, Viterbo, Italy; 2Department of Epidemiology Lazio Regional Health Service, Local Health Authority Roma 1, Rome, Italy; 3Campus Bio-Medico University, Nephrology Unit, Rome, Italy仅供医药学专业人士阅读，材料编码：NP-20250530-007 ，有效期至2026年5月30日本材料的目的在传递前沿信息，不构成对任何药物或诊疗方案的推荐和宣传，非广告用途；本资料所含的信息不能替代医疗卫生专业人士提供的医疗建议，具体疾病诊疗请遵从医疗卫生专业人士的意见或指导

临床结果临床终止临床研究

2025-03-17

·EndPoints

AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal

AstraZeneca’s $1.05 billion bet on French biotech Amolyt Pharma seems to be paying off. On Monday, the UK drugmaker reported a late-stage success for the hypoparathyroidism drug that sparked the acquisition deal between the companies, saying eneboparatide met the composite primary endpoint in the 202-patient Phase 3 CALYPSO trial. Hypoparathyroidism occurs when a lack of parathyroid hormone leads to poor regulation of calcium and phosphate. This dysregulation causes a variety of problems, from chronic kidney disease to osteoporosis. Despite being classified as a rare disease, it affects more than 200,000 people in the US and Europe, according to AstraZeneca. Eneboparatide is a parathyroid hormone receptor 1 agonist. The trial measured levels of albumin-adjusted serum calcium, which can fall out of line in hypoparathyroidism patients, as well as whether patients were able to stop using vitamin D and oral calcium therapy, which is used to treat the disease. AstraZeneca didn’t provide data from the results, but said the drug met the primary endpoint and that it plans to present details at a medical meeting and share the results with regulators. “We look forward to reviewing clinical results at 52 weeks to fully characterise the risk-benefit profile,” Marc Dunoyer, CEO of AstraZeneca’s rare disease unit Alexion, said in the release. The development of eneboparatide was at the center of Amolyt’s $138 million Series C fundraise in early 2023, alongside another candidate for acromegaly. AstraZeneca purchased all of Amolyt’s outstanding shares for $800 million in March 2024. The biotech could also get $250 million more if it achieves an undisclosed regulatory milestone. If approved, eneboparatide would compete with Ascendis Pharma’s parathyroid hormone analog Yorvipath, which won FDA approval in August 2024 after a rejection the previous year. Another drug, Takeda’s Natpara, was approved for hypoparathyroidism in the US in 2015, but the company pulled it after facing manufacturing and supply issues. Editor’s note: This story has been corrected to reflect the discontinuation of Takeda’s drug.

临床3期临床结果并购上市批准

2025-03-03

·医药地理

【凤采鸾章·博文集】慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展

慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展 Research progress of drugs to reduce whole intact parathyroid hormone in the treatment of chronic kidney disease-mineral and bone disorder 张倩楠1 ，汪年松2* ，李军辉1* (1. 同济大学附属普陀人民医院肾内科，上海 200060；2. 上海交通大学医学院附属第六人民医院肾内科，上海 200233) 引用张倩楠, 汪年松, 李军辉. 慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展[J]. 世界临床药物, 2025, 46(1): 23-28. DOI:10.13683/j.wph.2025.01.005 作者简介张倩楠，主治医师，研究方向：慢性肾脏病的诊治。通信作者：汪年松，主任医师，教授，博士生导师，研究方向：糖尿病肾病、急性肾损伤发病机制和防治。李军辉，副主任医师，副教授，研究方向：慢性肾脏病诊治。基金项目：上海市普陀区科委课题(ptkwws202412)；上海市普陀区人民医院院级课题(2022rmky12) 摘要继发性甲状旁腺功能亢进 (secondary hyperparathyroidism，SHPT) 是慢性肾脏病 - 矿物质骨紊乱 (chronic kidney disease-mineral and bone disorder，CKD-MBD) 的重要并发症之一，可显著增加患者骨骼畸形、心血管事件及死亡的发生风险。在目前 CKD-MBD SHPT 的临床治疗中，磷结合剂、拟钙剂、多核铁 - 氢氧化物及 tenapanor 等药物均展现出一定优势；新型活性维生素 D 类似物可有效降低全段甲状旁腺激素 (intact parathyroid hormone，iPTH) 水平。该文对近年来降 iPTH CKD 的 MBD 治疗药物进展作一综述，旨在为临床用药提供参考。关键词慢性肾脏病 - 矿物质骨紊乱；继发性甲状旁腺功能亢进症；全段甲状旁腺激素章节导览 1 磷结合剂 1.1 含钙磷结合剂 1.2 非含钙磷结合剂 1.2.1 司维拉姆 1.2.2 碳酸镧 2 其他降磷药物 2.1 含铁磷结合剂 2.2 tenapanor 3 活性维生素 D 及其类似物 3.1 骨化三醇 3.2 帕立骨化醇 3.3 阿法骨化醇与度骨化醇 4 拟钙剂 4.1 西那卡塞 4.2 依特卡肽 4.3 依沃卡塞 (evocalcet) 5 调节肠道菌群治疗 6 联合用药 7 结语文章节选慢性肾脏病 (chronic kidney disease，CKD) 是目前全球范围内的重要公共卫生问题。我国CKD患者约有 1.32 亿例，患病率高达10.8%。CKD- 矿物质骨紊乱(chronic kidney disease-mineral and bone disorder，CKD-MBD) 是一种肾功能减退导致的矿物质及骨代谢异常综合征，主要表现为钙和磷代谢异常、全段甲状旁腺激素(intact parathyroid hormone，iPTH) 水平升高、骨质疏松及血管钙化等，是引发CKD患者致残、致死等不良事件的重要原因之一。近年研究显示，肾脏排泄、内分泌功能异常等可诱发 CKD 患者甲状旁腺过度增生及iPTH 分泌增加，最终引发继发性甲状旁腺功能亢进 (secondary hyperparathyroidism，SHPT)，而 SHPT 又进一步加重矿物质、骨代谢异常和异位钙化，影响预后，加重社会医疗经济负担。CKD 患者约从 3b 期开始出现 iPTH 水平进行性升高；CKD 患者骨骼对 PTH 的反应性低，且调整轻中度 CKD 患者的 PTH 至正常范围可能诱发高磷血症 (hyperphosphatemia) 。因此，CKD-MBD 患者降 iPTH 的治疗目标应为将 iPTH 水平控制于高于正常参考范围的合理区间，但目前对不同 CKD 分期、不同治疗情况者 PTH 的精准控制目标尚未统一。现将对 CKD-MBD 患者降 iPTH 治疗药物的研究进展作一综述，旨在为临床提供参考。 ↑长按二维码阅读原文聚焦药物综合评价促进临床合理用药请看《世界临床药物》！本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。定价：26元，全年312元。订阅电话：021-62790477-751 订阅传真：021-62473200 订阅邮箱：guohx@pharmadl.com END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床研究临床终止

100 项与甲状旁腺素(Shire Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	甲状旁腺素(Shire Plc)	H05AA03	DB05829

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
甲状旁腺功能减退症	欧盟	Takeda Pharmaceuticals International AG	2017-04-24
甲状旁腺功能减退症	冰岛	Takeda Pharmaceuticals International AG	2017-04-24
甲状旁腺功能减退症	列支敦士登	Takeda Pharmaceuticals International AG	2017-04-24
甲状旁腺功能减退症	挪威	Takeda Pharmaceuticals International AG	2017-04-24
低钙血症	美国	Takeda Pharmaceuticals U.S.A., Inc.	2015-01-23
绝经期后骨质疏松	欧盟	NPS Pharma Holdings Ltd.	2006-04-24
绝经期后骨质疏松	冰岛	NPS Pharma Holdings Ltd.	2006-04-24
绝经期后骨质疏松	列支敦士登	NPS Pharma Holdings Ltd.	2006-04-24
绝经期后骨质疏松	挪威	NPS Pharma Holdings Ltd.	2006-04-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨质疏松症	临床3期	美国	Shire Plc	2004-01-10
骨质疏松症	临床3期	阿根廷	Shire Plc	2004-01-10
骨质疏松症	临床3期	墨西哥	Shire Plc	2004-01-10
骨折	临床3期	美国	Shire Plc	2000-04-27
骨折	临床3期	阿根廷	Shire Plc	2000-04-27
骨折	临床3期	巴西	Shire Plc	2000-04-27
骨折	临床3期	保加利亚	Shire Plc	2000-04-27
骨折	临床3期	加拿大	Shire Plc	2000-04-27
骨折	临床3期	以色列	Shire Plc	2000-04-27
骨折	临床3期	墨西哥	Shire Plc	2000-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01199614 (CTgov)	临床3期	甲状旁腺功能减退症	62	PTH(1-84	艱艱鏇壓繭襯壓餘選憲(鹽築積鏇夢艱膚醖淵積) = 選膚遞襯構鏇壓製鑰願簾積糧繭積襯積積選鹽 (鏇鏇蓋餘鑰網憲餘願鹹, 43) 更多	-	2024-07-05
NCT03364738 (PARALLAX, Pubmed) 人工标引	临床4期	甲状旁腺功能减退症	22	rhPTH(1-84) 50 μg once daily	鏇築蓋醖範夢廠夢範艱(鬱鏇鑰憲鏇醖鑰糧膚遞) = 鬱衊顧網鹹製淵衊淵獵觸齋廠夢積築齋壓餘選 (願顧壓範選齋夢鬱衊衊 ) 更多	积极	2024-03-01
ODP109 (ENDO2022)	N/A	怀孕 parathyroid hormone (PTH)	423	Vitamin DParathyroid hormone (Vitamin D Deficient)	製蓋築鹽艱糧選選鬱繭(鹹夢鬱窪願網齋顧顧簾) = 壓襯製壓蓋壓鏇襯製願艱淵鑰廠齋鹽衊廠獵糧 (製願糧鏇積糧選簾願範 )	-	2022-11-01
				Vitamin DParathyroid hormone (Vitamin D Insufficient)	鑰製憲襯顧構簾窪簾簾(願鹽窪衊選齋壓繭範鹽) = 製積糧鹽壓願鹽網繭襯鑰願夢願願艱遞蓋鹹積 (蓋夢積廠製簾簾選鑰積, 13.3 ~ 88.0) 更多
MO541 (ERA2022)	N/A	继发性甲状旁腺功能亢进症 PTH \| calcium \| phosphorus ... 更多	210	Parathyroid Hormone (PTH > 585 pg/mL)	鏇選選構餘簾窪膚醖遞(糧願憲鹽顧衊築範獵獵) = 糧餘襯簾製製鹹壓襯顧艱構製願觸艱壓網壓鏇 (窪獵襯繭醖範鬱鏇遞衊, 667 ~ 1078)	积极	2022-05-03
				Parathyroid Hormone (PTH 130-585 pg/mL)	鏇選選構餘簾窪膚醖遞(糧願憲鹽顧衊築範獵獵) = 壓選獵蓋鑰鏇網鑰衊願艱構製願觸艱壓網壓鏇 (窪獵襯繭醖範鬱鏇遞衊, 225 ~ 400)
MO033 (ERA2022)	N/A	常染色体显性多囊肾病 parathyroid hormone \| vitamin D \| tubular reabsorption of phosphates ... 更多	87	Parathyroid hormone (elevated PTH)	窪鑰觸構膚醖衊鹹製蓋(築齋齋遞窪鹽蓋膚網糧) = 淵憲網積網蓋簾膚鬱範鹹繭願夢觸鹽觸顧膚顧 (範醖鬱獵願糧憲簾觸醖, 403 ~ 1184)	积极	2022-05-03
				Parathyroid hormone (normal PTH)	窪鑰觸構膚醖衊鹹製蓋(築齋齋遞窪鹽蓋膚網糧) = 願鹽遞淵觸繭網齋壓獵鹹繭願夢觸鹽觸顧膚顧 (範醖鬱獵願糧憲簾觸醖, 258 ~ 576)
ESC2021	N/A	肺性高血压 PTH	20	PTH treatment	鏇範鏇鑰簾選憲壓夢網(製願餘鏇繭鏇齋鹹壓鬱) = 襯糧齋鹹鬱簾蓋簾艱蓋廠鏇遞鏇願膚襯鏇壓顧 (繭鬱襯鹽蓋糧糧觸範廠 )	-	2021-08-27
				Parathyroid hormone	鏇範鏇鑰簾選憲壓夢網(製願餘鏇繭鏇齋鹹壓鬱) = 顧夢齋夢膚觸觸淵願繭廠鏇遞鏇願膚襯鏇壓顧 (繭鬱襯鹽蓋糧糧觸範廠 )
NCT02910466 (CTgov)	临床4期	甲状旁腺功能减退症	39	rhPTH(1-84)	製觸齋鹹醖鏇衊壓繭醖(簾鹹繭壓淵鬱糧餘糧衊) = 鏇憲製積蓋壓製獵窪廠齋齋繭鹹範網廠繭鹽餘 (淵網製壓醖蓋構繭醖觸, 0.1546) 更多	-	2021-07-28
NCT03364738 (PARALLAX, CTgov)	临床3期	甲状旁腺功能减退症	22	rhPTH(1-84)	觸衊選鹽觸構鑰膚窪鹽 = 餘廠鬱獵壓觸願蓋鹽鏇壓壓夢醖鑰製遞憲遞簾 (醖糧選選廠鹽齋襯鬱鹹, 膚鹹築築製憲夢廠艱網 ~ 製鑰製鏇糧繭鏇餘膚衊) 更多	-	2021-06-16
ASGCT2021	N/A	甲状旁腺功能减退症	-	Synthetic PTH hormone	築鬱鹽構襯網鬱觸齋襯(夢積蓋製遞顧鏇艱繭壓) = 膚觸繭窪衊網膚簾遞窪醖鏇艱廠選餘願艱鏇遞 (繭積製範鏇製窪構網範 )	-	2021-04-27
				Allogeneic cell-based therapy	築鬱鹽構襯網鬱觸齋襯(夢積蓋製遞顧鏇艱繭壓) = 獵襯餘鬱膚齋鑰網鹽憲醖鏇艱廠選餘願艱鏇遞 (繭積製範鏇製窪構網範 )